David J. Grainger - Dec 31, 2023 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Innovation Officer
Signature
/s/ Gregory Weinhoff, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Dec 31, 2023
Transactions value $
-$37,412
Form type
4
Date filed
1/2/2024, 07:41 PM
Previous filing
Oct 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Tax liability -$37.4K -4.7K -0.49% $7.96 963K Dec 31, 2023 Direct F1, F2
holding CNTA Ordinary Shares 27.5K Dec 31, 2023 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

David J. Grainger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
F3 Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.